VIDEO: Olezarsen reduces high triglyceride, ApoC-III levels
Click Here to Manage Email Alerts
ATLANTA — In this Healio video exclusive, Erica S. Spatz, MD, MHS, discusses research into lipid disorders from the American College of Cardiology Scientific Session, examining studies aimed at reducing high triglycerides.
Spatz, an associate professor of cardiology and epidemiology at Yale University School of Medicine, discussed one study that tested the apolipoprotein C-III blocker olezarsen (Ionis Pharmaceuticals), which saw positive results in reducing triglyceride levels along with ApoC-III levels.
“I’m excited about this drug because this is an option for people who have high triglyceride levels. We’re seeing the triglyceride levels be cut in half, and the safety profile was excellent,” Spatz said.
Collapse
Read more about
Click Here to Manage Email Alerts